Insight Molecular Diagnostics (IMDX) Q2 2026 earnings summary

Executive summary

• Progressing toward FDA marketing authorization for GraftAssureDx, with regulatory review in advanced stages and additional information requested by the FDA; a recent SIR meeting was planned to align on data submission requirements.

• Favorable Medicare and MolDX reimbursement changes, including expanded coverage for dd-cfDNA transplant testing and increased allowable testing frequency, boost commercial potential.

• Strong clinical and head-to-head data demonstrate equivalence or superiority to leading assays, driving interest from top U.S. transplant centers, reference labs, and supporting expanded clinical roles.

• Strategic partnership with Bio-Rad supports FDA engagement, development, and commercialization of transplant products, including GraftAssureCore, GraftAssureIQ, and GraftAssureDx.

• Transitioning from a development-stage to a revenue-generating business, with investments made ahead of anticipated commercialization and a focus on kit sales post-FDA authorization.

Financial highlights

• Q2 2026 revenue was $239,000, primarily from laboratory services, with $21,000 from research-use-only kits; net loss for Q2 was $11.3 million, and adjusted EBITDA loss was $7.8 million.

• Gross margin for Q2 2026 was 65.7%, with gross profit of $157,000.

• Operating expenses totaled $11.6 million, including $2.3 million non-cash loss from contingent consideration and $661,000 in stock-based compensation.

• Cash, cash equivalents, and restricted cash at June 30, 2026, were $18.7 million; accumulated deficit was $416.3 million.

• February 2026 registered direct offering raised $26.0 million gross ($24.6 million net), including investment from Bio-Rad.

Outlook and guidance

• Targeting FDA marketing authorization for GraftAssureDx later this year, with ongoing dialogue and timing dependent on agency review.

• Cash burn expected to moderate, with future investments tied to revenue growth and outgoing free cash flow projected to narrow in the second half of 2026.

• Exploring options to extend cash runway if FDA authorization is delayed, including accelerating registry enrollment.

• R&D expenses projected to stabilize as focus shifts to clinical evidence generation and registry studies.

• Management believes cash on hand is sufficient for at least the next twelve months.